Market research
MITRA.BR Mithra Pharmaceuticals SA
BR EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 14M
- P/E ratio
- Not available
- Analyst target
- 0.8
- Dividend yield
- Not available
- Beta
- 0.48
Profile
Company facts
- Exchange
- BR
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- BE0974283153
- Market cap
- 14M
- P/E ratio
- Not available
- Analyst target
- 0.8
- Dividend yield
- Not available
- Beta
- 0.48
About
About Mithra Pharmaceuticals SA
Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Belgium, Europe and internationally. Its development candidates include Estelle, a combined oral contraceptive that has completed phase III clinical trial; Donesta, which is in phase III clinical trial for estetrol-based oral hormone treatment; and products for neuroprotection and wound healing. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a tablet composed of tibolone and a synthetic steroid used for hormone therapy in menopause; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications. In addition, it provides products in polymeric forms, implants, sterile injectable products, and hormonal tablets. The company was founded in 1999 and is headquartered in Liège, Belgium.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the MITRA.BR discussion.
5 years, 5 months ago
Mithra Pharmaceuticals SA is currently in a long term downtrend where the price is trading 0.5% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 12.9.
Mithra Pharmaceuticals SA's total revenue sank by 96.7% to $3M since the same quarter in the previous year.
Its net income has dropped by 153.8% to $-34M since the same quarter in the previous year.
Finally, its free cash flow fell by 9.8% to $-24M since the same quarter in the previous year.
Based on the above factors, Mithra Pharmaceuticals SA gets an overall score of 1/5.